LivingGLP1
Study S002311

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

ClinicalTrials.gov record

Registration

Registration
NCT06243536
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
SINGLE
Status
UNKNOWN
Enrollment
60
Start
2024-02-01
Primary completion
2024-12-31
Lead sponsor
University Hospital Sestre Milosrdnice
Conditions
Type 2 Diabetes; Overweight; Disordered Eating Behaviors
Interventions
DRUG:Semaglutide; DRUG:standard of care
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Eating Attitude Test (EAT-26) questionnaire score [EAT-26 questionnaire will be assessed at the beginning of the trial and at the end of the trial after 12 weeks.]

Linked records (16)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0011935Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Diabetes, obesity & metabolism
2023Randomized trialPMID 36722623DOIregistry reference BACKGROUND:36722623
R0006529Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ, Frontiers in endocrinology
2021Other trialPMID 34248838DOIregistry reference BACKGROUND:34248838
R0007787GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA, Molecular metabolism
2021Narrative reviewPMID 33068776DOIregistry reference BACKGROUND:33068776
R0007876Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.
Tommerdahl KL, Advances in chronic kidney disease
2021Narrative reviewPMID 34922690DOIregistry reference BACKGROUND:34922690
R0008791An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Pratley RE, Diabetes, obesity & metabolism
2021Other trialPMID 34286894DOIregistry reference BACKGROUND:34286894
R0019611Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
Da Porto A, Diabetes & metabolic syndrome
2020Randomized trialPMID 32289741DOIregistry reference BACKGROUND:32289741
R0010984Recent updates on GLP-1 agonists: Current advancements & challenges.
Sharma D, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2018Narrative reviewPMID 30372907DOIregistry reference BACKGROUND:30372907
R0011685Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature.
McElroy SL, Medical hypotheses
2018Randomized trialPMID 29407005DOIregistry reference BACKGROUND:29407005
R0024077Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ, Cell metabolism
2018Narrative reviewPMID 29617641DOIregistry reference BACKGROUND:29617641
R0025397Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
Frías JP, Diabetes, obesity & metabolism
2017Randomized trialPMID 27527911DOIregistry reference BACKGROUND:27527911
R0025853Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.
FLAT-SUGAR Trial Investigators, Diabetes care
2016Randomized trialPMID 27208320DOIregistry reference BACKGROUND:27208320
R0013774Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Jensterle M, Endocrine research
2015Other trialPMID 25330463DOIregistry reference BACKGROUND:25330463
R0021434Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
Robert SA, Obesity research & clinical practice
2015Randomized trialPMID 25870084DOIregistry reference BACKGROUND:25870084
R0030407Glucagon-like peptide-1: glucose homeostasis and beyond.
Cho YM, Annual review of physiology
2014Narrative reviewPMID 24245943DOIregistry reference BACKGROUND:24245943
R0055711From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph Anthony DeFronzo, Diabetes
2009OtherPMID 19336687DOIregistry reference BACKGROUND:19336687
R0027857Biology of incretins: GLP-1 and GIP.
Baggio LL, Gastroenterology
2007Narrative reviewPMID 17498508DOIregistry reference BACKGROUND:17498508